IL310442A - FUSED BICYCLIC heteroaryl compounds are useful as NLRP3 inhibitors - Google Patents
FUSED BICYCLIC heteroaryl compounds are useful as NLRP3 inhibitorsInfo
- Publication number
- IL310442A IL310442A IL310442A IL31044224A IL310442A IL 310442 A IL310442 A IL 310442A IL 310442 A IL310442 A IL 310442A IL 31044224 A IL31044224 A IL 31044224A IL 310442 A IL310442 A IL 310442A
- Authority
- IL
- Israel
- Prior art keywords
- compounds useful
- bicyclic heteroaryl
- fused bicyclic
- heteroaryl compounds
- nlrp3 inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21203314 | 2021-10-19 | ||
| EP22174872 | 2022-05-23 | ||
| PCT/EP2022/078755 WO2023066825A1 (en) | 2021-10-19 | 2022-10-17 | Fused bicyclic heteroaryl compounds useful as nlrp3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310442A true IL310442A (en) | 2024-03-01 |
Family
ID=84359071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310442A IL310442A (en) | 2021-10-19 | 2022-10-17 | FUSED BICYCLIC heteroaryl compounds are useful as NLRP3 inhibitors |
Country Status (15)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| WO2024023266A1 (en) * | 2022-07-28 | 2024-02-01 | Ac Immune Sa | Novel compounds |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| JP2026508178A (ja) * | 2023-02-14 | 2026-03-10 | シェンチェン ジョンジー バイオロジカル テクノロジー カンパニー, リミテッド | Nlrp3を阻害する化合物及びその製造方法と応用 |
| CN120958000A (zh) | 2023-04-19 | 2025-11-14 | 豪夫迈·罗氏有限公司 | 噁唑并[4,5-b]吡嗪和噁唑并[4,5-b]吡啶衍生物作为nlrp3抑制剂用于治疗例如炎症性疾病 |
| WO2025067343A1 (zh) * | 2023-09-27 | 2025-04-03 | 纽欧申医药(上海)有限公司 | 并环化合物及其应用 |
| WO2025099241A1 (en) * | 2023-11-10 | 2025-05-15 | Evotec International Gmbh | Nlrp3 modulators |
| TW202535370A (zh) * | 2023-12-14 | 2025-09-16 | 美商默沙東有限責任公司 | 作為nod樣受體蛋白3抑制劑之吲唑衍生物 |
| US20250223290A1 (en) * | 2023-12-14 | 2025-07-10 | Merck Sharp & Dohme Llc | Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3 |
| CN122580319A (zh) * | 2024-01-05 | 2026-08-14 | 北京普祺医药科技股份有限公司 | 杂环化合物及其药物组合物 |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3及glp-1a組合療法 |
| WO2025172260A1 (en) * | 2024-02-12 | 2025-08-21 | Evotec International Gmbh | Nlrp3 modulators |
| WO2025172521A1 (en) * | 2024-02-15 | 2025-08-21 | Evotec International Gmbh | Nlrp3 modulators |
| WO2026054623A1 (ko) * | 2024-09-09 | 2026-03-12 | (주) 업테라 | 신규 nlrp3 억제제 화합물 |
| WO2026128279A1 (en) * | 2024-12-09 | 2026-06-18 | Merck Sharp & Dohme Llc | Pyrazine benzimidazole derivatives useful as inhibitors of nod-like receptor protein 3 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102116166B1 (ko) * | 2017-09-20 | 2020-05-27 | 건국대학교 글로컬산학협력단 | Nlrp3 억제제 |
| EP3953360B1 (en) | 2019-04-09 | 2024-02-28 | F. Hoffmann-La Roche AG | Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl) |
| AR119731A1 (es) * | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| CN115279739B (zh) * | 2020-03-27 | 2025-07-22 | 尼科治疗有限公司 | 取代哒嗪化合物 |
-
2022
- 2022-10-17 IL IL310442A patent/IL310442A/en unknown
- 2022-10-17 AU AU2022369332A patent/AU2022369332A1/en active Pending
- 2022-10-17 CA CA3228369A patent/CA3228369A1/en active Pending
- 2022-10-17 EP EP22803219.9A patent/EP4419532A1/en active Pending
- 2022-10-17 PE PE2024000806A patent/PE20241176A1/es unknown
- 2022-10-17 CR CR20240158A patent/CR20240158A/es unknown
- 2022-10-17 MX MX2024004503A patent/MX2024004503A/es unknown
- 2022-10-17 KR KR1020247012834A patent/KR20240088922A/ko active Pending
- 2022-10-17 WO PCT/EP2022/078755 patent/WO2023066825A1/en not_active Ceased
- 2022-10-17 JP JP2024523187A patent/JP2024539068A/ja active Pending
- 2022-10-17 AR ARP220102819A patent/AR127386A1/es unknown
- 2022-10-18 TW TW111139412A patent/TW202330545A/zh unknown
-
2024
- 2024-04-11 CL CL2024001106A patent/CL2024001106A1/es unknown
- 2024-04-11 CO CONC2024/0004552A patent/CO2024004552A2/es unknown
- 2024-04-17 US US18/637,966 patent/US20240279237A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022369332A1 (en) | 2024-02-08 |
| PE20241176A1 (es) | 2024-05-28 |
| CA3228369A1 (en) | 2023-04-27 |
| EP4419532A1 (en) | 2024-08-28 |
| CR20240158A (es) | 2024-05-22 |
| US20240279237A1 (en) | 2024-08-22 |
| AR127386A1 (es) | 2024-01-17 |
| JP2024539068A (ja) | 2024-10-28 |
| KR20240088922A (ko) | 2024-06-20 |
| TW202330545A (zh) | 2023-08-01 |
| MX2024004503A (es) | 2024-05-06 |
| CL2024001106A1 (es) | 2024-10-18 |
| CO2024004552A2 (es) | 2024-04-29 |
| WO2023066825A1 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4067359A4 (en) | PYRIMIDOIMIDAZOLE COMPOUNDS AS DNA-PK INHIBITORS | |
| IL307188A (en) | NLRP3 inhibitors | |
| SG11202011299PA (en) | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | |
| IL286966B2 (en) | History of bicyclic heteroaryl compounds as phosphodiesterase ectonucleotide pyrophosphatase inhibitors | |
| IL254277A0 (en) | Fused bicyclic heteroaryl derivatives with activity as inhibitors of the prolyl hydroxylase domain | |
| EP4137484A4 (en) | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | |
| SG11202013016YA (en) | Heterocyclic compounds as trk inhibitors | |
| EP3774812A4 (en) | MACROCYCLIC COMPOUNDS AS TRK CINEMA INHIBITORS | |
| SG11202008705TA (en) | Heteroaryl compounds as kinase inhibitor | |
| IL300211B1 (en) | Antagonist compounds | |
| IL290367A (en) | Fused ring heteroaryl compounds as ripk1 inhibitors | |
| IL319011A (en) | Triazinone derivatives as NLRP3 inhibitors | |
| IL319009A (en) | Triazinone derivatives as NLRP3 inhibitors | |
| IL308071A (en) | Process for preparing NLRP3 inhibitors | |
| GB202019622D0 (en) | Antagonist compounds | |
| AU2024392169A1 (en) | Bicyclic heteroaryl compounds | |
| EP3313852A4 (en) | Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors | |
| EP4293018A4 (en) | COMPOUND AS NLRP3 INHIBITOR | |
| IL289023A (en) | Bicyclic heterocyclic compounds as inhibitors of bcdin3d activity | |
| PT4337652T (pt) | Inibidores do nlrp3 | |
| IL309342A (en) | Pyrimidine compounds for use as MAP4K1 inhibitors | |
| IL314955A (en) | Substituted bicyclic heteroaryl compounds useful as inhibitors of tlr9 | |
| CA3280702A1 (en) | Bicyclic imide compounds as trpa1 inhibitors | |
| HK40118761A (en) | Substituted bicyclic heterocycles as malt-1 inhibitors | |
| EP4359399A4 (en) | EP2 antagonist compounds |